Blood type matching is strongly preferred in kidney transplantation, but it is no longer an absolute requirement. For decades, transplanting a kidney across the ABO blood group barrier was considered too dangerous to attempt, because the recipient’s immune system would attack the mismatched organ almost immediately. That changed with the development of desensitization protocols, which suppress the antibody response enough to let an incompatible kidney survive and function. Today, thousands of ABO-incompatible kidney transplants are performed worldwide, with outcomes that come surprisingly close to those of matched transplants.
Why Blood Type Used to Be a Dealbreaker
The ABO blood group antigens are not just on red blood cells. They sit on the surface of cells lining blood vessels throughout the body, including the vessels inside a transplanted kidney. If you receive a kidney carrying a blood group antigen your body does not recognize as its own, your immune system treats the organ the way it would treat a mismatched blood transfusion. Preformed antibodies latch onto those antigens and trigger a chain reaction of inflammation, clotting, and tissue destruction called antibody-mediated rejection. In the worst cases, this can destroy a transplanted kidney within hours or days.
This is why ABO incompatibility was historically treated as an absolute barrier to kidney transplantation, and most transplant programs still follow standard ABO matching rules as the default.1Europe PMC. ABO incompatibility in renal transplantation The same basic logic applies that you learned about blood transfusions: type O is the universal donor, type AB is the universal recipient, and types A and B can donate to their own type or to AB. But unlike a bag of blood, a kidney is a scarce, life-saving organ, and waiting years for a perfectly matched one from a deceased donor has its own serious risks. That tension is what drove transplant medicine to figure out how to cross the blood type barrier.
How Desensitization Makes Mismatched Transplants Possible
The core idea behind ABO-incompatible transplantation is straightforward: if the recipient’s anti-blood-group antibodies are the problem, remove them before surgery and keep them from coming back afterward. In practice, this involves two strategies used together: removing the existing antibodies from the recipient’s blood and suppressing the immune cells that produce new ones.2PubMed Central. Current protocols and outcomes of ABO-incompatible kidney transplantation
Antibody removal typically uses a procedure similar to dialysis, where the patient’s blood is filtered through a device that strips out the offending antibodies. This might be done several times in the weeks leading up to surgery. On the immune suppression side, patients receive drugs that target the B cells responsible for antibody production. A common regimen includes rituximab (which depletes B cells), along with standard transplant immunosuppression drugs like tacrolimus and mycophenolate mofetil.3PubMed Central. Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience Some earlier protocols also required removing the spleen, though that has largely fallen out of favor as drug-based approaches improved.
The evolution from those early, aggressive interventions to today’s more refined protocols took decades. The first intentional ABO-incompatible kidney transplant happened in Boston in 1951, and the patient died within a month. For years afterward, the medical consensus was that blood-type-incompatible transplantation simply should not be attempted. Japan, facing an extreme shortage of deceased-donor organs, became the leader in reviving the approach in the 1980s, eventually developing the antibody-removal and immunosuppression strategies that form the basis of modern protocols.4PubMed Central. ABO-incompatible renal transplantation: From saline flushes to antigen-specific immunoadsorption-Tools to overcome the barrier
How Well Do ABO-Incompatible Transplants Actually Work?
Remarkably well. A meta-analysis pooling data from multiple transplant centers found that one-year graft survival for ABO-incompatible recipients was about 96%, compared with 98% for ABO-compatible controls at the same centers.5PubMed Central. ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis That two-percentage-point gap is statistically real but clinically small, and it narrows even further at some high-volume centers with extensive experience.
Long-term data from Japan, where these transplants have been performed the longest, tell a nuanced story. One large study reported nine-year graft survival of about 59% for ABO-incompatible transplants versus 57% for a historical control group of compatible transplants, a difference that was not statistically significant.6American Journal of Transplantation. Excellent Long-term Outcome of ABO-Incompatible Living Donor Kidney Transplantation in Japan The one-year numbers slightly favored the compatible group, but over time the gap essentially vanished. These findings give transplant teams confidence that an ABO-incompatible kidney, properly managed, can serve a patient for many years.
What Happens After Transplant: The Mystery of Accommodation
One of the more fascinating aspects of ABO-incompatible transplantation is a phenomenon called accommodation. After the initial desensitization period, the recipient’s anti-blood-group antibodies eventually return. You might expect them to attack the transplanted kidney, since the kidney still carries the mismatched blood group antigens. But in most cases, the kidney keeps functioning normally despite the return of those antibodies.7PubMed Central. Accommodation in ABO-incompatible organ transplants
Researchers have studied this extensively. In one investigation, all sixteen patients examined at one year still had donor blood-group antigens present in their grafts and anti-blood-group antibodies circulating in their blood. Yet thirteen of the sixteen had completely normal kidney function and healthy-looking tissue on biopsy. The kidney cells appeared to have activated protective mechanisms, including changes in how they handle inflammation signals and resist cell death, essentially shielding themselves from injury.8American Journal of Transplantation. Accommodation in ABO-Incompatible Kidney Allografts, a Novel Mechanism of Self-Protection Against Antibody-Mediated Injury Accommodation is not fully understood, and questions remain about why it develops in some patients and not others, but it is one of the reasons ABO-incompatible transplants can succeed long-term.9PubMed Central. Accommodation in renal transplantation: unanswered questions
The A2 Subtype Shortcut
Not all blood type A kidneys are created equal. The A blood group has subtypes, and one of them, called A2, expresses far fewer A antigens on cell surfaces than the more common A1 subtype. This means a kidney from an A2 donor provokes a much weaker immune response in a type B or type O recipient. Some transplant programs have taken advantage of this by allocating A2 kidneys to B and O recipients who have naturally low levels of anti-A antibodies, without requiring the full desensitization protocol used for other ABO-incompatible transplants.
A ten-year experience at one center found that when recipients were selected based on low antibody levels, A2 kidney transplants achieved a two-year graft survival rate of about 94%, compared with 88% for concurrent ABO-compatible deceased-donor transplants at the same center.10PubMed. Ten-year experience in transplantation of A2 kidneys into B and O recipients In other words, these particular “mismatched” kidneys actually performed slightly better than the standard matched ones, likely because patients were carefully selected and the organs spent less time waiting to be allocated. This approach has been adopted by several allocation systems as a way to expand the donor pool, particularly for type B and O recipients who otherwise wait the longest.
Does Rh Factor Matter?
When people think about blood type, they usually think of both the ABO group and the Rh factor (the “positive” or “negative” part). In blood transfusions, Rh mismatch can cause serious problems. In kidney transplantation, though, Rh factor is far less important. Rh antigens are found on red blood cells but are not significantly expressed on the cells of the kidney itself, so the recipient’s immune system does not target a transplanted kidney based on Rh status.
An older study did find an association between the recipient being Rh-positive and having better transplant outcomes, but this was not attributed to Rh matching between donor and recipient.11Tissue Antigens. Some Important Factors in Cadaver‐Donor Kidney Transplantation In routine clinical practice, transplant teams do not require Rh matching for kidney allocation. You can safely receive a kidney from an Rh-positive donor if you are Rh-negative, or vice versa.
The Blood Type O Waiting Problem
Blood type has a major practical impact on how long you wait for a deceased-donor kidney, and people with type O blood get the worst deal. Under standard allocation rules, type O recipients can only receive kidneys from type O donors. Meanwhile, type O donors are “universal” in the sense that their kidneys lack A and B antigens, so they can be given to recipients of any blood type. The result is that type O kidneys sometimes go to non-O recipients, while O recipients accumulate on the waiting list.
Data from European transplant registries showed that type O patients waited a median of 85 months for a deceased-donor kidney, compared with 59 months for non-O patients. That extra wait was not just an inconvenience: type O patients had a higher risk of dying before ever receiving a transplant, roughly 13% versus about 10% for non-O patients.12PubMed. The ‘blood group O problem’ in kidney transplantation–time to change? Allocation policy experts have studied ways to address this inequity, and some reforms have narrowed the gap, but it remains a real challenge in many transplant systems worldwide.13European Journal of Operational Research. Eliminating transplant waiting time inequities – With an application to kidney allocation in the USA
This waiting-time disparity is one of the strongest arguments in favor of ABO-incompatible transplantation from living donors. If you are type O and have a willing family member or friend who is type A or B, an ABO-incompatible living-donor transplant may get you off dialysis years sooner than waiting for a matched deceased-donor organ.
The Trade-Offs of Crossing the Blood Type Barrier
Desensitization protocols work, but they come with real costs. The extra immunosuppression needed to prevent antibody-mediated rejection leaves patients more vulnerable to infections in the early months after transplant. A national study of Medicare-insured recipients found that ABO-incompatible transplant recipients had roughly double the risk of pneumonia and about 55% higher risk of urinary tract infections in the first 90 days, compared with ABO-compatible recipients. Wound infections and bleeding complications were also more common.14PubMed Central. Early clinical complications after ABO incompatible live donor kidney transplantation: A national study of Medicare-insured recipients These risks are manageable, and they tend to diminish after the first year as immunosuppression is tapered, but they are an important part of the conversation between patients and transplant teams.
Monitoring antibody levels closely after surgery also matters. Transplant centers track the levels of anti-blood-group antibodies to watch for dangerous rebounds. Newer and more sensitive laboratory methods for measuring these antibody titers are improving the ability to catch problems early.15PubMed Central. Evaluation of different methods for antibody titre determination in ABO-incompatible kidney transplantation Some centers have even begun using machine-learning tools to predict which patients are at highest risk for antibody rebound based on their pre-transplant profiles, allowing for more tailored treatment.16PubMed Central. Impact of IgG monitoring and machine learning based prediction on outcomes of ABO incompatible kidney transplantation in blood type O recipients
Cost Compared with Staying on Dialysis
ABO-incompatible transplants cost more upfront than standard matched transplants, mainly because of the antibody-removal sessions, extra drugs, and closer monitoring. But the relevant comparison is not just incompatible versus compatible transplant; it is incompatible transplant versus years of dialysis while waiting for a matched organ. One analysis estimated the incremental cost of an ABO-incompatible transplant over a standard compatible transplant at roughly $126,000 over ten years. That sounds like a lot until you consider that dialysis runs about $87,500 per year, meaning a patient who waits the average 4.5 years on dialysis racks up over $390,000 in treatment costs before even getting to the transplant itself.17PubMed Central. Economic impacts of ABO incompatible live donor kidney transplantation: A national study of Medicare-insured recipients
A systematic review confirmed this picture across different healthcare systems: ABO-incompatible transplantation, though costlier than a matched transplant, remains cost-effective when measured against long-term dialysis.18PubMed Central. Economic Evaluations of Kidney Paired Donation, ABO-Incompatible Kidney Transplantation, and Maintenance Dialysis in Different Resource Settings: A Systematic Review From both a financial and a quality-of-life standpoint, getting a working kidney sooner tends to win, even if it means crossing the blood type barrier.
Children Get a Natural Advantage
Young children have an interesting immunological quirk that makes ABO-incompatible transplantation easier for them. Infants and toddlers have not yet developed high levels of anti-blood-group antibodies, because those antibodies are formed in response to gut bacteria and environmental exposures that build up over the first years of life. This means very young recipients sometimes do not need the antibody-removal steps that adults require.
One study demonstrated successful ABO-incompatible living-donor kidney transplants in children without any antibody removal, at least in those with low pre-transplant antibody levels.19PubMed. ABO-incompatible pediatric kidney transplantation without antibody removal A case report described the first ABO-incompatible deceased-donor kidney transplant in an infant, an O-type baby who received an A-type kidney. Because the infant’s antibody levels were extremely low, no desensitization was performed before or after surgery. At nearly a year post-transplant, the child was thriving with normal kidney function.20PubMed Central. Case Report: Successful ABO-Incompatible Deceased Donor Kidney Transplantation in an Infant Without Pre-transplant Immunological Treatment These cases suggest the blood type barrier is more of a spectrum than a wall, and for the youngest patients, it may barely exist.
Why Japan Led the Way
The geography of ABO-incompatible transplantation is not random. Japan performed far more of these procedures, far earlier, than Western countries, and the reason is cultural and structural. Deceased-organ donation rates in Japan have historically been among the lowest in the developed world, driven by traditional views about the integrity of the body after death and a legal framework that made brain-death determination difficult. With very few deceased-donor kidneys available, Japanese transplant teams had a powerful incentive to make living-donor transplants work across blood type barriers.21PubMed. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan
This practical necessity turned Japan into the proving ground for desensitization protocols. By the time Western transplant centers began seriously considering ABO-incompatible transplantation in the 2000s, Japanese programs already had over a decade of outcome data showing it could work. That head start is part of why long-term survival data from Japan are so extensive and why some of the best evidence for accommodation comes from Japanese transplant registries.
Beyond ABO: Minor Blood Group Antigens
While ABO compatibility gets most of the attention, the kidney also expresses antigens from several lesser-known blood group systems. Research has identified that antigens from the Kidd, Duffy, MNS, and Lewis blood group systems are present on kidney tissue, meaning antibodies against those antigens could theoretically cause problems in a transplant.22PubMed. The potential role of antibodies against minor blood group antigens in renal transplantation
One study using a kidney-specific model confirmed that Duffy and Kidd antigens can act as minor targets for the immune system in transplanted kidneys.23PubMed. Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection? In practice, these minor antigens are not routinely matched or screened in standard kidney transplant workups, partly because their clinical impact appears small compared with ABO and the major tissue-matching system (HLA). But for patients who experience unexplained rejection episodes despite good ABO and HLA matching, these minor antigens are an area that some researchers think deserves more attention.
Enzymatic Conversion: Turning Any Kidney into Type O
Perhaps the most exciting frontier in this space is the idea of enzymatically converting a donor kidney’s blood type before transplanting it. Instead of suppressing the recipient’s immune system, you would chemically strip the problematic antigens off the organ itself, turning it into the functional equivalent of a type O kidney that any recipient could accept.
Researchers have already demonstrated this in the lab. One team used enzymes from the gut bacterium Flavonifractor plautii to remove about 80% of blood group A antigens from human kidneys within two hours, using a machine-perfusion system that pumps the enzyme solution through the organ outside the body. The treated kidneys no longer bound anti-A antibodies and did not activate the immune cascade that leads to rejection.24PubMed Central. Enzymatic conversion of human blood group A kidneys to universal blood group O A separate group achieved something similar with type B kidneys using an enzyme from a different bacterium.25PubMed Central. Enzymatic blood group conversion of human kidneys during ex vivo normothermic machine perfusion
Neither approach has been tested in actual transplant patients yet, and significant questions remain about durability, safety, and whether partial antigen removal is sufficient in real-world conditions. But if the technique eventually reaches the clinic, it could eliminate the ABO barrier entirely, not just for kidneys but potentially for hearts, livers, and other organs as well. It would also reshape the waiting list, since blood type O patients would no longer be stuck waiting only for O donors. The science is still early-stage, but transplant researchers are watching it closely.